3D生物打印癌症模型：从基础生物学到药物开发
2022-11-25 16:50:30
SCI
13 November 2022
3D bioprinted cancer models: from basic biology to drug development
（Nature Reviews Cancer; IF: 69.800）
Lena Neufeld, Eilam Yeini, Sabina Pozzi, Ronit Satchi-Fainaro
CORRESPONDENCE TO: ronitsf@tauex.tau.ac.il
Abstract |
Effort
invested in the development of new drugs often fails to be translated
into meaningful clinical benefits for patients with cancer. The
development of more effective anticancer therapeutics and accurate
prediction of their clinical merit remain urgent unmet medical needs. As
solid cancers have complex and heterogeneous structures composed of
different cell types and extracellular matrices, three-dimensional (3D)
cancer models hold great potential for advancing our understanding of
cancer biology, which has been historically investigated in tumour cell
cultures on rigid plastic plates. Advanced 3D bioprinted cancer models
have the potential to revolutionize the way we discover therapeutic
targets, develop new drugs and personalize anticancer therapies in an
accurate, reproducible, clinically translatable and robust manner. These
ex vivo cancer models are already replacing existing in vitro systems
and could, in the future, diminish or even replace the use of animal
models. Therefore, profound understanding of the differences in
tumorigenesis between 2D, 3D and animal models of cancer is essential.
This Review presents the state of the art of 3D bioprinted cancer
modelling, focusing on the biological processes that underlie the
molecular mechanisms involved in cancer progression and treatment
response as well as on proteomic and genomic signatures.
新药研发往往无法为癌症患者提供有意义的临床益处。开发更有效的抗癌疗法并准确预测其临床价值仍然是亟待满足的医疗需求。由于实体癌具有由不同细胞类型和细胞外基质组成的复杂且异质的结构，3D癌症模型在促进我们对癌症生物学的理解方面具有巨大的潜力，并且已经在肿瘤细胞培养中有一定的研究。先进的3D生物打印癌症模型有可能以准确、可复制、临床可翻译和稳健的方式彻底改变我们发现治疗靶点、开发新药和个性化抗癌治疗的方式。这些体外癌症模型已经在取代现有的体外系统，未来可能会减少甚至取代动物模型的使用。因此，深入了解2D、3D和动物癌症模型之间的肿瘤发生差异至关重要。本文综述了3D生物打印癌症建模的最新技术，重点关注癌症进展和治疗反应的分子机制的生物学过程以及蛋白质组学和基因组学特征。
